Aclaris Therapeutics, Inc.

Company identity

• Aclaris Therapeutics, Inc. and its subsidiaries (referred to as “Aclaris,” the “Company,” “we,” “us,” and “our” in the report).

Brand names mentioned

• KINect
• RHOFADE
• All brand names or trademarks appearing in the Annual Report are the property of their respective owners.

Nature of the document section provided

• The text is from Part I, Item 1A (Risk Factors) of the Annual Report.
• It contains a standard forward-looking statements disclaimer, including:
  • Forward-looking statements may prove inaccurate and may be material.
  • Readers should not rely on these statements as guarantees of future results.
  • The statements reflect views as of the date of the Annual Report; subsequent events may change those views.
  • The company may elect to update these statements in the future, but has no obligation to do so, except as required by law.

Table of contents (sections listed in the excerpt)

• PART I
• Item 1. Business (page 4)
• Item 1A. Risk Factors (page 22)
• Item 1B. Unresolved Staff Comments (page 64)
• Item 1C. Cybersecurity (page 64)
• Item 2. Properties (page 65)
• Item 3. Legal Proceedings (page 66)
• Item 4. Mine Safety Disclosures (page 66)

To prepare a numbers-based summary

• Please provide the Company’s business description (Item 1: Business) and/or the most recent financial statements or a section containing employee counts, revenue, and net income. I can summarize those precisely.